A Translatable Nanoprodrug Integrates Traditional Chinese and Western Medicines for Chemo-Immunotherapy of Hepatocellular Carcinoma via Ferroptosis
ACS Applied Materials & Interfaces · 2025
DOI: 10.1021/acsami.5c18878 ↗At a glance
Journal article in ACS Applied Materials & Interfaces, 2025. Written by Xiaojie Wei and 7 co-authors. Institution: Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, Universi…. Major MEDLINE topics: Carcinoma, Hepatocellular, Liver Neoplasms, Ferroptosis, Prodrugs. Cited 1 times so far (Crossref); 70 references. Funded by: National Natural Science Foundation of China, Health Research Project of Hunan Provincial Health Commission, Hunan Science and Technology Innovation Leading Talent Project.
Abstract (original language)
Integrating traditional Chinese and Western medicine (TCWM) represents a promising therapeutic strategy for many malignant diseases, including hepatocellular carcinoma (HCC) by leveraging the complementary strengths of each therapeutic species, which, however, remains relatively unexplored to our knowledge. Herein we develop FANPs, a carrier-free nanoprodrug self-assembled from a binary prodrug based on 5-fluorouracil (5-FU) and a traditional Chinese medicine derivative, 3,19-isopropyl andrographolide (IPADE) connected via an ester link for chemo-immunotherapy of HCC. IPADE can not only induce ferroptosis and CD8+ T cells infiltration but also show cytotoxicity greater than that of the parent ADE. A breakthrough of this nanoprodrug development is a traditional core idea (5-FU) encapsulated in an emerging framework (TCWM integration) design. FANPs achieve a high tumor growth inhibition (TGI) of 89.1% in a C57BL/6J mouse model, which outperforms significantly the therapeutic efficiencies of the groups treated with either a single 5-FU (TGI: 22.2%), IPADE (53.3%) or a physically mixed dosage (61.8%). Further combination use of FANPs with a PD-1/PD-L1 small molecule inhibitor boosts adaptive immunity, which ultimately leads to a superior TGI of 97.6% in a murine HCC model. Overall, this study not only reveals ADE and its derivatives' antitumor properties, but also develops a carrier-free nanoplatform based on the concept of integrated TCWM as a translatable technology for potential clinical treatment of HCC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang 421001, China.
- Affiliated Hospital of Hunan Academy of Chinese Medicine, Hunan Academy of Chinese Medicine, Changsha 410006, China.
ORCID profiles: Cui-Yun Yu, Hua Wei
Funding
- National Natural Science Foundation of China
- Health Research Project of Hunan Provincial Health Commission
- Hunan Science and Technology Innovation Leading Talent Project
- Key R&D Program of Hunan Province
- Natural Science Foundation of?Hunan Province
Cite
APA
Wei, X., Cao, Z., Zhou, H., Zhang, J., Liu, S., Liu, J., Yu, C. Y., & Wei, H. (2025). A Translatable Nanoprodrug Integrates Traditional Chinese and Western Medicines for Chemo-Immunotherapy of Hepatocellular Carcinoma via Ferroptosis. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.5c18878
Vancouver
Wei X, Cao Z, Zhou H, Zhang J, Liu S, Liu J, et al. A Translatable Nanoprodrug Integrates Traditional Chinese and Western Medicines for Chemo-Immunotherapy of Hepatocellular Carcinoma via Ferroptosis. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.5c18878
BibTeX
@article{Wei2025,
author = {Wei, Xiaojie and Cao, Zhen and Zhou, Haoyuan and Zhang, Jinyan and Liu, Songbin and Liu, Jinjie and Yu, Cui-Yun and Wei, Hua},
title = {A Translatable Nanoprodrug Integrates Traditional Chinese and Western Medicines for Chemo-Immunotherapy of Hepatocellular Carcinoma via Ferroptosis},
journal = {ACS Applied Materials & Interfaces},
year = {2025},
doi = {10.1021/acsami.5c18878}
}
EUVIMED